Oragenics partners with Duck Flats Pharma to support FDA IND trial design

Oragenics ( OGEN ) announced it has engaged Duck Flats Pharma as its U.S. Investigational New Drug, IND, readiness and regulatory execution partner to support FDA-facing preparation and clinical trial design as the Company advances its novel intranasal concussion therapy toward U.S.-based development. The engagement is intended to align the Company's upcoming Phase 2a clinical trial in Australia with its U.S regulatory strategy. "We highly value our collaboration with DUCK FLATS Pharma as we advance our IND strategy for ONP-002 and prepare for future U.S. clinical development," said Janet Huffman, Chief Executive Officer of Oragenics.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >","yLinkElement":"context_link","yModuleName":"content-canvas","yTrafficOrigin":"content-canvas default"}" rel="noopener noreferrer nofollow"> Try Now>>

>","yLinkElement":"context_link","yModuleName":"content-canvas","yTrafficOrigin":"content-canvas default"}" rel="noopener noreferrer nofollow"> See today's best-performing stocks on TipRanks >>

Read More on OGEN:

Disclaimer & Disclosure Report an Issue

• Oragenics Extends At-the-Market Equity Sales Agreement

• Oragenics files $100M mixed securities shelf

• Oragenics Adjusts Executive Compensation Plan